Abcam, ab258034, Human LTA4H (Leukotriene A4 hydrolase) knockout HEK-293T cell lysate

Size: 1Kit
LTA4H KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 10 bp deletion in exon 2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 10 bp deletion in exon 2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-LTA4H, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Leukotriene A4 hydrolase often called LTA4H is an enzyme that converts leukotriene A4 into leukotriene B4 an important mediator in inflammation. It has a molecular mass of approximately 69 kDa and functions as a zinc metalloprotease. Expression of LTA4H is widespread detected in various tissues including the lung liver and kidney. This enzyme plays an essential role in modulating inflammatory responses due to its ability to catalyze the transformation of leukotriene A4.
Biological function summary
Leukotriene A4 hydrolase (LTA4H) transforms leukotriene A4 an unstable epoxide into leukotriene B4 a potent chemoattractant. The enzyme does not function within a multi-protein complex but interacts with small molecules during leukotriene biosynthesis. Leukotriene B4 produced by LTA4H recruits neutrophils to sites of inflammation enhancing immune defense. While its primary function is promoting inflammation this activity also regulates the resolution phase by facilitating tissue repair and return to homeostasis.
Pathways
Leukotriene A4 hydrolase plays a role in the arachidonic acid cascade an important biological pathway for synthesizing eicosanoids. This pathway involves several steps where arachidonic acid releases from cell membrane phospholipids and converts to intermediate leukotriene A4 by 5-lipoxygenase. LTA4H then converts leukotriene A4 into leukotriene B4 which orchestrates inflammatory responses. LTA4H connects to proteins like 5-lipoxygenase which also acts within this cascade.
Leukotriene A4 hydrolase associates with inflammatory diseases such as asthma and inflammatory bowel disease. In asthma the overproduction of leukotriene B4 can exacerbate airway inflammation and hyperresponsiveness. Here leukotrienes interact with receptors on effector cells which contributes to the pathology of asthma. Inflammatory bowel disease showcases a similar link where increased levels of leukotriene B4 potentiate intestinal inflammation. Effective management of these conditions may involve targeting leukotriene pathways specifically inhibiting the activity of LTA4H to ameliorate symptoms.